Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT04215224
Recruiting Observational

Histopathology Images Based Survival Prediction of Glioma Patients Using Artificial Intelligence

NCT04215224 · tracked via the Priya Life Science China tracker
Sponsor
The First Affiliated Hospital of Zhengzhou University
Phase
Observational
Started
2017-01-01
Last updated
2021-02-08

Condition(s) studied

Glioma

Investigational drug(s) / intervention(s)

Histopathology images based survival prediction for glioma patients

Histopathology images based survival prediction for glioma patients: Histopathology images based survival prediction of glioma patients in the frame of molecular pathology by leveraging AI

Study summary

This registry aims to collect clinical, molecular and histopathology imaging including detailed survival data, clinical parameters, molecular pathology (1p/19q codeletion, MGMT methylation, IDH and TERTp mutations, etc) and images of HE slices in primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine hstopathology imaging based algorithms that able to predict patients' survivals in the frame of molecular pathology or subgroups of gliomas.

Eligibility

Sex
ALL
Min age
1 Year
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Patients must have radiologically and histologically confirmed diagnosis of primary glioma * Life expectancy of greater than 3 months * Must receive tumor resection * Signed informed consent Exclusion Criteria: * No gliomas * No sufficient amount of tumor tissues for detection of molecular pathology * Patients who are pregnant or breast feeding * Patients who are suffered from severe systematic malfuctions

Primary outcome measure(s)

  • AUC of survival prediction performance — up to 10 years
    AUC of survival prediction performance=sensitivity+specificity-1

Trial sites (1)

FacilityCityRegionStatus
Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University Zhengzhou Henan Recruiting

More The First Affiliated Hospital of Zhengzhou University trials in China

Prognostic Value of Neurometabolic Networks in CRC (PVNM-CRC) Recruiting
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma Enrolling by invitation
Newborns From Patients Treated With ART (Assisted Reproductive Technology) Recruiting
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL Recruiting
Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer Starting soon

Other trials for the same condition

Tumor Vaccines for Solid Tumors Recruiting
The Clinical Application Value of CAIX-Targeted PET Hypoxia Imaging in Malignant Tumors Active, not recruiting
Study of GC101 TIL in Brain Glioma (Soochow2) Recruiting
PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique Starting soon
Prospective Real-World Study of Pathology AI for Glioma Molecular Prediction Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04215224 on ClinicalTrials.gov ↗ ← All trials in China